<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>List of repurposed drugs under clinical trial for COVID-19.</p>
 </caption>
 <alt-text id="alttext0040">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drugs</th>
    <th>Type</th>
    <th>Target</th>
    <th>Status</th>
    <th>Refs.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Camostat mesylate</td>
    <td align="left">Serine protease inhibitor</td>
    <td align="left">TMPRSS2</td>
    <td align="left">Under phase 1 and 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Nafamostat mesylate</td>
    <td align="left">Serine protease inhibitor</td>
    <td align="left">TMPRSS2</td>
    <td align="left">Under phase 2 and 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Chloroquine phosphate</td>
    <td align="left">Antimalarial</td>
    <td align="left">ACE-2</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Hydroxy-chloroquine</td>
    <td align="left">Antimalarial</td>
    <td align="left">Endosome, pH elevation</td>
    <td align="left">Still in Controversy</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">Antiviral</td>
    <td align="left">RdRp</td>
    <td align="left">Under clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Umifenovir</td>
    <td align="left">Antiviral</td>
    <td align="left">Membrane fusion, clathrin-mediated endocytosis</td>
    <td align="left">Under phase 4 of clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Favipiravir</td>
    <td align="left">Antiviral</td>
    <td align="left">RdRp</td>
    <td align="left">Inconsistent results in clinical trials</td>
    <td align="left">[
     <xref rid="bib73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Lopinavir</td>
    <td align="left">Protease inhibitor</td>
    <td align="left">3clpro, plpro</td>
    <td align="left">Inconsistent results in clinical trials</td>
    <td align="left">[
     <xref rid="bib63" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Antiviral</td>
    <td align="left">RdRp</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib63" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Arbidol</td>
    <td align="left">Antiviral</td>
    <td align="left">ACE2</td>
    <td align="left">Under clinical trials</td>
    <td align="left">[
     <xref rid="bib63" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Baricitinib</td>
    <td align="left">Rheumatoid arthritis</td>
    <td align="left">JAK kinase</td>
    <td align="left">Under clinical trials</td>
    <td align="left">[
     <xref rid="bib63" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Ritonavir</td>
    <td align="left">Antiviral</td>
    <td align="left">Protease inhibitor</td>
    <td align="left">Inconsistent results in completed clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">EIDD-2801</td>
    <td align="left">Antiviral</td>
    <td align="left">Viral replication</td>
    <td align="left">Prepared for clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Tociliczumab</td>
    <td align="left">mAb</td>
    <td align="left">IL-6 pathway</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Sarilumab</td>
    <td align="left">mAb</td>
    <td align="left">IL-6 pathway</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Bevacizumab</td>
    <td align="left">mAb</td>
    <td align="left">VEGF pathway</td>
    <td align="left">Under clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Vitamin C</td>
    <td align="left">Dietary supplements</td>
    <td align="left">Boost immunity</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Vitamin D</td>
    <td align="left">Dietary supplements</td>
    <td align="left">Boost immunity</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Azithromycin</td>
    <td align="left">Antibiotic</td>
    <td align="left">mRNA translation</td>
    <td align="left">Under phase 4 of clinical trials</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Corticosteroids</td>
    <td align="left">Corticosteroids</td>
    <td align="left">Dampen pro-inflammatory cytokines and possess antifibrotic property</td>
    <td align="left">Still in controversy</td>
    <td align="left">[
     <xref rid="bib61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Clevudine</td>
    <td align="left">Antiviral</td>
    <td align="left">Blocks DNA supply of virus to nucleus</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Isotretinoin</td>
    <td align="left">Retinoid</td>
    <td align="left">Against PLPro</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Ivermectin and Nitazoxanide</td>
    <td align="left">Antiparasitic</td>
    <td align="left">Inhibit import in alpha/beta receptor</td>
    <td align="left">Under phase 2 and 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Deferoxamine</td>
    <td align="left">Chelating agents</td>
    <td align="left">Inhibit IL6 synthesis through decreasing NF-Kb.</td>
    <td align="left">Under phase 1 and 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Dexamethasone</td>
    <td align="left">Steroid</td>
    <td align="left">Anti-inflammatory action</td>
    <td align="left">Under phase 4 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Piclidenoson</td>
    <td align="left">A3 adenosine receptor agonist</td>
    <td align="left">Inhibit cytokine storm</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Tranexamic acid</td>
    <td align="left">Antifibrinolytics</td>
    <td align="left">Inhibit conversion of plasminogen to plasmin</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">BLD-2660</td>
    <td align="left">Antiviral</td>
    <td align="left">Targets IL6</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Sildenafil citrate</td>
    <td align="left">Phospho-diesterase inhibitor</td>
    <td align="left">Dilates blood vessles</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Losartan</td>
    <td align="left">Angiotensin II receptor antagonist</td>
    <td align="left">Targets ACE2</td>
    <td align="left">Under phase 1 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Telmisartan</td>
    <td align="left">Antifibrotic</td>
    <td align="left">Angiotensin receptor blocker</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Atorvastatin</td>
    <td align="left">Statin</td>
    <td align="left">Target NF-kB</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Prazosin</td>
    <td align="left">Alpha-blockers</td>
    <td align="left">Prevent cytokine storm</td>
    <td align="left">Under phase 2 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Chlorpromazine</td>
    <td align="left">Antipsychotics</td>
    <td align="left">Inhibit viral replication</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Lenalidomide</td>
    <td align="left">Antiangiogenic agent</td>
    <td align="left">For multiple myeloma patients</td>
    <td align="left">Under phase 4 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Ruxolitinib</td>
    <td align="left">Anti-inflammatory</td>
    <td align="left">Targets cytokine storm</td>
    <td align="left">Under phase 3 of clinical trials</td>
    <td align="left">[
     <xref rid="bib13" ref-type="bibr">13</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
